Prevalence of Anti-Ganglioside Antibodies and Their Clinical Correlates with Guillain-Barré Syndrome in Korea: A Nationwide Multicenter Study

Jong Kuk Kim, Jong Seok Bae, Dae-Seong Kim, Susumu Kusunoki, Jong Eun Kim, Ji Soo Kim, Young-Eun Park, Ki-Jong Park, Hyun Seok Song, Sun Young Kim, Jeong-Geun Lim, Nam-Hee Kim, Bum Chun Suh, Tai-Seung Nam, Min Su Park, Young-Chul Choi, Eun Hee Sohn, Sang-Jun Na, So Young Huh, Ohyun Kwon, Su-Yun Lee, Sung-Hoon Lee, Sun-Young Oh, Seong-Hae Jeong, Tae-Kyeong Lee, Dong Uk Kim

*Department of Neurology, College of Medicine, Dong-A University, Busan, Korea, †Department of Neurology, College of Medicine, Hallym University, Seoul, Korea, ‡Department of Neurology, School of Medicine, Pusan National University, Busan, Korea, §Department of Neurology, School of Medicine, Kyungpook National University, Daegu, Korea, ‖Department of Neurology, College of Medicine, University of Ulsan, Ulsan, Korea, ‡Department of Neurology, School of Medicine, Keimyung University, Daegu, Korea, †Department of Neurology, College of Medicine, Sungkyunkwan University, Seoul, Korea, ‡Department of Neurology, Chungnam National University, Daejeon, Korea, †Department of Neurology, College of Medicine, Kangnung National University, Daejeon, Korea, ‡Department of Neurology, College of Medicine, Konyang University, Daejeon, Korea, †Department of Neurology, College of Medicine, Chosun University, Gwangju, Korea, ‖Department of Neurology, College of Medicine, Soonchunhyang University, Seoul, Korea.

Correspondence
Jong Seok Bae, MD, PhD
Department of Neurology, Kangdong Sacred Heart Hospital, College of Medicine, Hallym University, 150 Seongan-ro, Gangdong-gu, Seoul 134-701, Korea
Tel +82-2-2224-2854
Fax +82-2-2224-2114
E-mail jsb_res@hotmail.co.kr

Copyright © 2014 Korean Neurological Association

Background and Purpose No previous studies have investigated the relationship between various anti-ganglioside antibodies and the clinical characteristics of Guillain-Barré syndrome (GBS) in Korea. The aim of this study was to determine the prevalence and types of anti-ganglioside antibodies in Korean GBS patients, and to identify their clinical significance.

Methods Serum was collected from patients during the acute phase of GBS at 20 university-based hospitals in Korea. The clinical and laboratory findings were reviewed and compared with the detected types of anti-ganglioside antibody.

Results Among 119 patients, 60 were positive for immunoglobulin G (IgG) or immunoglobulin M antibodies against any type of ganglioside (50%). The most frequent type was IgG anti-GM1 antibody (47%), followed by IgG anti-GT1a (38%), IgG anti-GD1a (25%), and IgG anti-GQ1b (8%) antibodies. Anti-GM1-antibody positivity was strongly correlated with the presence of preceding gastrointestinal infection, absence of sensory symptoms or signs, and absence of cranial nerve involvement. Patients with anti-GD1a antibody were younger, predominantly male, and had more facial nerve involvement than the antibody-negative group. Anti-GT1a-antibody positivity was more frequently associated with bulbar weakness and was highly associated with ophthalmoplegia when coupled with the coexisting anti-GQ1b antibody. Despite the presence of clinical features of acute motor axonal neuropathy (AMAN), 68% of anti-GM1- or anti-GD1a-antibody-positive cases of GBS were diagnosed with acute inflammatory demyelinating polyradiculoneuropathy (AIDP) by a single electrophysiologic study.
Introduction

Guillain-Barré syndrome (GBS) is an acute polyradiculoneuropathy characterized by ascending muscle weakness and areflexia. Immune-mediated mechanisms are thought to be responsible for the pathogenesis of GBS. Although this condition has been the subject of considerable research over several decades, no clear pathophysiological target of human acute inflammatory demyelinating polyradiculoneuropathy (AIDP) has been found. In contrast, a direct causative relationship has been found between acute motor axonal neuropathy (AMAN) and anti-ganglioside antibodies. Recent studies have demonstrated the existence of an association between gangliosides and autoimmune mechanisms. Evidence for this association has been gleaned from experimental studies demonstrating the cross-reactivity of autoantibodies induced by ganglioside antigens against the axolemma of the host’s peripheral nerves. Many other studies have demonstrated that this molecular mimicry hypothesis is most consistent with Campylobacter jejuni infection.

Several of the anti-ganglioside antibodies, including anti-GM1, GM1b, GD1a, and N-acetylgalactosaminyl GD1a (GalNAc-GD1a), are common in GBS sufferers from Asian countries and are representative markers of AMAN. It was recently revealed that these antibodies are important in determining the electrophysiological characteristics of GBS. Uncini et al. found that some anti-ganglioside-antibody-positive cases that were initially classified as demyelinating or undetermined types following nerve conduction studies (NCSs) were ultimately revealed to be axonal type on follow-up NCSs. Thus, an accurate classification of GBS subtypes requires serial NCSs. Moreover, this study demonstrated that the assay of anti-ganglioside antibodies can be a useful tool for determining the type of GBS at an early stage in the disease.

It is known that diverse clinical features of variant GBS cases can be attributed to each anti-ganglioside antibody. For example, the anti-GT1a antibody is the key factor underlying bulbar and brachial palsies in GBS, and the anti-GQ1b antibody is known to be a specific primary factor underlying Miller Fisher syndrome (MFS), and can explain the oculomotor palsy and other cranial-nerve involvement found in GBS. Therefore, investigation of the anti-ganglioside antibodies provides an opportunity to improve the understanding of diverse manifestations of GBS and the related pathomechanisms. The aim of this study was thus to determine the frequency of anti-ganglioside antibodies in GBS and related clinical syndromes in a Korean population. In addition, the efficacy of conventional electrophysiological study for the diagnosis of AMAN in Koreans was determined.

Methods

Study design

Data were collected from GBS patients admitted to 20 university-based hospitals in Korea. Among the 574 patients who expressed a desire to participate in the anti-ganglioside antibody study for acute peripheral neuropathies during the period of January 2008 to December 2009, 119 clinically compatible GBS cases met the defined criteria and were selected as study subjects. Patients with MFS, Bickerstaff’s brainstem encephalitis (BBE), or other atypical variants such as a pharyngeal-cervical-brachial (PCB) variant were not included in this study. During the study period, 38, 3, and 5 patients with anti-GQ1b antibody syndrome including classical MFS, BBE, and PCB with positive anti-GT1a antibody, respectively, were encountered. Data regarding the patients’ age, sex, type of preceding infection, presenting symptoms, neurological signs, treatment, and cerebrospinal fluid (CSF) findings were analyzed. The GBS disability score, as defined by Hughes et al., was used in this study. Neurological signs were further classified according to the presence of cranial nerve involvement such as oculomotor palsy, facial nerve palsy or oropharyngeal weakness, respiratory disturbances requiring mechanical ventilation, and objective sensory changes.

Anti-ganglioside antibody study

Serum samples were obtained from patients during the acute stage within 2 weeks of symptom onset. An enzyme-linked immunosorbent assay (ELISA) was used to detect the various types of anti-ganglioside antibodies, including immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies against the gangliosides GM1, GM2, GM3, GD1a, GD1b, GD3, GT1a, and...
Anti-Ganglioside-Antibody-Positive Guillain-Barré Syndrome in Korea

GT1b, and GQ1b, as described previously. Although they are not true gangliosides, testing was also performed for galactocerebroside and asialo-GM1. The presence and types of anti-ganglioside antibodies were analyzed by researchers who were blinded to the patients’ presenting neurological signs and electrophysiological classifications.

Electrophysiological classification
Electrophysiological evaluations were made based on the neurologists’ decisions to choose primary axonal form or demyelination when they requested ELISA for anti-ganglioside antibodies. An initial NCS was performed within 2 weeks of the onset of motor weakness, as described earlier. The median, ulnar, peroneal, and tibial nerves were selected for motor NCSs, and the median, ulnar, and sural nerves were selected for sensory NCSs. F-wave evaluations were also conducted from all selected motor nerves. Accordingly, all patients were classified as having primary demyelinating, primary axonal, or unclassified GBS. Findings of primary axonal or primary demyelinating GBS were further classified as either pure motor or sensorimotor types using electrophysiological parameters. All findings were interpreted by each referring neurology specialist who was blinded to the anti-ganglioside antibody results.

Standard protocol and patient consent
The data for all patients were compiled using a standardized protocol that was reviewed and approved by the ethical committee at the Dong-A University Medical Center, Busan, Korea. Furthermore, informed consent to participate was obtained from all patients or their caregivers.

Statistical analysis
Statistical analysis was performed using Statistical Analysis System (SAS) version 9.0 (SAS Institute Inc., Cary, NC, USA). With respect to the clinical features of the GBS patients, differences in proportions between groups were tested using the chi-square test or Fisher’s exact test, and differences in medians were tested using the Mann-Whitney U test. Two-sided tests were used throughout, and the level of statistical significance was set at $p<0.05$.

Results
Demographics of patients with anti-ganglioside antibodies
In total, 119 GBS patients (diagnosed using the relevant criteria) were analyzed, of which 79 were men and 40 were women. The age at onset ranged from 15 to 80 years (median 55.4 years). Seventy-three patients (61%) had a history of preceding infection, and 60 (50%) were positive for IgG or IgM antibodies against the various types of gangliosides. Of those 60, 58 were positive for IgG-type anti-ganglioside antibodies and 8 were positive for IgM antibodies; thus, 6 of the IgM-positive cases were simultaneously positive for IgG-type anti-ganglioside antibodies.

Analysis of the clinical findings according to the presence of any type of anti-ganglioside antibody revealed that the antibody-positive group had a higher ratio of men, a younger age at onset, more frequent preceding gastrointestinal events with a short interval from infection to motor weakness, less frequent sensory symptoms or signs, and a lower level of CSF proteins (Table 1). Immunomodulating treatment was performed in 87% and 83% of patients from each antibody-positive and -negative group during the acute stage. The modality was intravenous human immunoglobulin in all treated patients, regardless of additional plasmapheresis. Motor disability scores on admission, and at 4 weeks and 3 months thereafter.

| Table 1. Comparison of the clinical characteristics between the anti-ganglioside-antibody-positive and -negative groups |
|---------------------------------|----------------|--------|
| Proportion of men              | Positive (n=60) | Negative (n=59) | p     |
| Age (years)                    | Median, 47.8   | Median, 54.7   | 0.030 |
| Preceding infection            | 49 (82%)       | 33 (56%)      | 0.002 |
| Gastrointestinal infection vs. upper-respiratory-tract infection | 23:19         | 5:26      | 0.001 |
| Interval from infection to symptom onset (days) | 6.3±4.5     | 9.8±6.3       | 0.025 |
| Objective sensory signs        | 8 (13%)        | 34 (58%)      | 0.001 |
| Respiratory disturbance requiring mechanical ventilation | 16 (27%)   | 12 (20%)     | 0.416 |
| Cranial nerve abnormalities    | 29 (48%)       | 33 (56%)      | 0.352 |
| Cerebrospinal fluid protein (mg/dL) | 45.5±25.6  | 86.9±74.9      | 0.001 |
| Motor disability score on admission | 2.6±1.1     | 2.9±1.1       | 0.091 |
| Motor disability score at 4 weeks | 3.2±1.3  | 3.4±1.2       | 0.316 |
| Motor disability score at 3 months | 1.6±1.5 | 1.4±1.2     | 0.386 |

Except where specified otherwise, the data are n (%) or mean±SD values.
The clinical significance of each anti-ganglioside antibody

Among the patients who were anti-ganglioside-antibody positive, the most frequent was IgG anti-GM1 antibody (28 patients, 47%), followed by IgG anti-GT1a (23 patients, 38%), and anti-GD1a (15 patients, 25%) antibodies (including overlapping cases) (Fig. 1). Anti-GQ1b antibodies were also found in ten patients, all of whom were also positive for anti-GT1a antibody.

Anti-GM1-antibody-positive cases

Anti-GM1-antibody positivity was strongly correlated with the presence of preceding gastrointestinal infection (61%, p=0.001), negative sensory signs (14%, p=0.001), absence of cranial nerve involvement (25%, p=0.006), and a lower CSF protein level (p=0.004) compared with the antibody-negative group. Motor function score and the frequency of respiratory disturbance requiring mechanical ventilation did not differ significantly from the antibody-negative group.

Anti-GD1a-antibody-positive cases

Patients with anti-GD1a antibody exhibited a similar pattern to the anti-GM1-positive group, with a younger onset age (median 41.3 years, range 25–72 years; p=0.003), frequent occurrences in men (86%, p=0.037), and fewer sensory signs (0%, p<0.001) compared with the antibody-negative group. Anti-GD1a-antibody positivity was frequently associated with facial diplegia, regardless of other accompanying antibodies or the absence of anti-ganglioside antibodies (10/15, 66%; p=0.066).

Overlap syndrome of cranial neuropathy associated with anti-GT1a with/without anti-GQ1b antibody

In addition to the typical anti-GM1 antibody related to AMAN pattern, the present results revealed that a large proportion of the patients had anti-GT1a or anti-GQ1b positivity. The IgG anti-GT1a antibody was frequently associated with cranial nerve abnormality (17/23, 74%; p=0.001) (Fig. 2). Compared with the IgG anti-GM1-antibody-positive group, presence of the anti-GT1a antibody was strongly associated with oropharyngeal weakness or other lower cranial neuropathies (16/23, 70% vs. 4/28, 14%; p<0.001). Although ophthalmoplegia appeared to occur more frequently in the anti-GT1a-positive group compared with the anti-GM1-positive group (8/23, 35% vs. 3/27, 11%), the difference was not significant (p=0.084). The simultaneous presence of the IgG anti-GQ1b antibody was more common in the anti-GT1a-positive group than in the anti-GM1-positive group (8/23, 44% vs. 1/28, 4%; p=0.001). Extraocular muscle weakness was strongly correlated with the co-occurrence of anti-GQ1b antibody in the anti-GT1a-positive group (6/10 anti-GQ1b-antibody-positive cases) (Fig. 2). IgG anti-GD1a-antibody positivity was more
The data are

common in the anti-GT1a-antibody-positive group than in the anti-GM1-antibody-positive group (9/23, 39% vs. 2/28, 7%; \( p=0.014 \)). Only four cases were simultaneously positive for anti-GM1 and anti-GT1a antibodies, among whom one was also positive for anti-GD1a antibody and another was also positive for anti-GQ1b antibody.

Cases positive for other types of antibody
There was positivity for other minor antibodies against gangliosides GT1b, GD1b, asialo-GM1, GD3, and galactocerebroside in nine, four, three, one, and one case, respectively, regardless of other coexisting anti-ganglioside antibodies. However, there was no clinical significance for these cases. None of the cases were positive for either anti-GM2 or anti-GM3 antibodies. There were no isolated IgG anti-GQ1b-antibody-positive cases.

Correlation between electrophysiological and anti-ganglioside antibody findings
Anti-GM1 and anti-GD1a antibodies are known to be axonal markers, but the patients who were positive for these antibodies did not exhibit significant differences in terms of the proportion of primary axonal pattern at initial NCS in comparison to those who were negative for those antibodies (27% vs. 20% mean, 7.3 days from symptom onset; \( p=0.693 \)) (Table 2). All of the diagnoses were made by neurology specialists on the basis of a single, conventional NCS. Twenty-eight of the 41 patients who were positive for IgG anti-GM1 or anti-GD1a antibodies were classified as having primary demyelination at the initial NCS; 21 cases exhibited a pure motor presentation and only 7 patients displayed typical sensoriomotor demyelinating polyneuropathy. Conversely, 37 of the 41 antibody-negative patients who were classified as having primary demyelination exhibited a classical sensoriomotor polyneuropathy pattern (Table 2).

Discussion
This is the first investigation of anti-ganglioside antibodies and their clinical significance in Korean GBS. The findings show that half of the included Korean GBS patients were positive for various types of anti-ganglioside antibody. The high frequency of anti-ganglioside antibodies revealed herein suggests that they are a continuum of the results obtained in China and Japan.\(^5,20,22\) Thus, compared to western countries, the proportion of AMAN seems to be higher in Korea, and similar to those reported in eastern Asian countries. The clinical findings of the antibody-positive group were clearly different from those of the antibody-negative group, although the classes of antibodies detected were diverse. The clinical findings of the antibody-positive group included male predominance, frequent preceding gastrointestinal infection, short interval from infection to motor weakness, negative sensory signs, and lower CSF levels of protein. These findings were also evident when the anti-GM1- or anti-GD1a-positive group was compared with the antibody-negative group. However, a considerable number of the patients who were anti-ganglioside-antibody positive were classified electrophysiologically as having demyelinating GBS. Therefore, the present findings also reaffirm the previous suggestion that using a single electrophysiological test can result in the erroneous misdiagnosis of AMAN as AIDP.\(^7\) Overall, it can be assumed that regardless of the electrophysiological classification, half of all Korean GBS patients exhibit the axonal type.

Previous studies have revealed that anti-ganglioside-antibody-positive cases, such as anti-GM1- or anti-GD1a-positive, exhibited different clinical manifestations compared to those with antibody-negative GBS.\(^5,22,24\) This finding is attributable to differences in the pathomechanisms of AMAN and AIDP. Although the underlying pathophysiology of AIDP is obscure, damage to the myelin sheath of the sensory and motor nerves by cellular immunity was suggested to occur in AIDP.\(^3\) In contrast, several recent studies have provided important information regarding the immunological mechanisms underlying AMAN pathology. According to these studies, the core factor is destruction of the paranodal axolemma induced by humoral autoimmunity, including anti-ganglioside antibodies and the complement system.\(^25,27\)

One particularly notable finding of the present study was the high frequency of IgG-type anti-GT1a-antibody positivity in Korean GBS. Originally, the anti-GT1a antibody was determined to be a specific marker of the PCB variant of GBS.\(^28\) This antibody is closely related to the ophthalmoplegia, facial diplegia, or bulbar palsy.\(^5,29\) Since the MFS and PCB variants of GBS were excluded from the present study, the positivity of this antibody in GBS had particular significance.
with respect to various clinical manifestations. The presence of anti-GT1a antibody resulted in a high proportion of patients with bulbar weakness compared with the anti-GM1-positive group. Anti-GQ1b-antibody positivity within the anti-GT1a group may be responsible for the coexisting ophthalmoplegia; this finding can be explained by cross-reaction with gangliosides of a similar structure. Although we do not know the difference from typical MFS cases, one interesting point is that anti-GQ1b-antibody positivity in this series does not appear to be associated with ataxia (only three cases).

Among the different types of cranial neuropathy, facial diplegia was found in 40 patients. The frequency of facial weakness did not differ significantly between the antibody-positive and -negative groups. However, in the antibody-positive group, facial diplegia was strongly associated with the presence of anti-GD1a antibody in this study. Although facial diplegia is a common manifestation of GBS, it can be an isolated sign or a presenting manifestation in some GBS patients. Some authors have suggested that prominent facial diplegia is correlated with accompanying anti-GD1a-antibody positivity, although GD1a ganglioside was originally found mainly in the ventral horn and motor fibers of the cauda equina.

Electrophysiological evaluation is an important part of understanding the pathomechanism underlying GBS. It is strongly correlated with the presence of anti-ganglioside antibodies, and especially that of GM1, GM1b, GD1a, and GalNAc-GD1a as axonal markers. The results of NCSs were compared between anti-GM1- or anti-GD1a-antibody-positive and -negative groups. Unexpectedly, the prevalence of either the axonal or demyelinating subtypes did not differ significantly between these two groups at the initial evaluation according to the NCS criteria. Previous studies have shown that some AMAN patients exhibit transient conduction blocks in the intermediate and distal nerve segments, mimicking demyelination—a condition known as reversible conduction failure. This rapidly reversible conduction block, which resolves within days to a few weeks, is found frequently in AMAN patients. This time course suggests functional or microstructural changes at the nodes of Ranvier, rather than segmental demyelination and remyelination: thus, serial NCS is required to confirm the fate of conduction block or axonal degeneration.

The interpretation of the electrophysiological results is limited by only one NCS being conducted in most cases, with no long-term follow up. Although it was not possible to analyze long-term follow-up results, it was noted that the pattern of involvement in the antibody-positive group appeared to be quite different from that in the antibody-negative group. A high proportion of anti-ganglioside-antibody-positive GBS patients exhibited a pure motor type, while most of the antibody-negative GBS patients had typical sensorimotor involvement. It is thus possible that some of the antibody-positive GBS patients could be classified as exhibiting demyelination according to the initial, single NCS criteria, such as prolonged terminal latency or conduction block. Unfortunately, we were unable to analyze the detailed factors contributing to the classification of each case in this study; however, we speculate that the presence of anti-ganglioside antibody and a pure motor presentation on NCS could reflect a different pathological background from that of classical sensorimotor GBS without anti-ganglioside antibodies. In this sense, studies of anti-ganglioside antibodies are important to understanding the various subtypes and manifestations of GBS.

The prognosis did not differ significantly between the anti-ganglioside-antibody-positive and -negative groups. It could be speculated that this is because Korean GBS patients have the opportunity to be treated with intravenous immunoglobulin in the acute stage of the disease, with the support of the national insurance system. Early treatment could halt the reversible conduction failure and prevent axonal degeneration even in AMAN patients. However, this study was subject to important limitations, such as the follow-up period being too short (3 months) and the interpretation of the electrophysiological characteristics being limited. However, it was found that a high proportion of Korean GBS patients expressed a variety of anti-ganglioside antibodies, which may explain the observed diverse clinical characteristics.

Conflicts of Interest

The authors have no financial conflicts of interest.

Acknowledgements

This work was supported by a Dong-A University research fund.

REFERENCES

1. Ashbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1996;27 Suppl:S21-S24.
2. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 2005; 366:1653-1666.
3. Kusunoki S, Shimizu J, Chiba A, Ugawa Y, Hitoshi S, Kanazawa I. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol 1996;39:424-431.
4. Yuki N, Yamada M, Koga M, Odaka M, Susuki K, Tagawa Y, et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 2001;49:712-720.
5. Yuki N. Ganglioside mimicry and peripheral nerve disease. Muscle Nerve 2007;35:691-711.
6. Sekiguchi Y, Uncini A, Yuki N, Misawa S, Notturno F, Nasu S, et al. Antiganglioside antibodies are associated with axonal Guillain-Barré syndrome: a Japanese-Italian collaborative study. J Neurol Neurosurg Psychiatry 2012;83:23-28.
7. Uncini A, Manzoli C, Notturno F, Capasso M. Pitfalls in electodiagnosis of Guillain-Barré syndrome subtypes. J Neurol Neurosurg Psychiatry 2010;81:1157-1163.
8. Lee SH, Lim GH, Kim JS, Oh SY, Kim JK, Cha JK, et al. Acute ophthalmoplegia (without ataxia) associated with anti-GQ1b antibody. Neurology 2008;71:426-429.
9. Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Clinical correlates of serum anti-GT1a IgG antibodies. J Neurol Sci 2004;219:139-145.

10. Miyazaki T, Kusunoki S, Kaida K, Shinu M, Kanazawa I. Guillain-Barré syndrome associated with IgG monospecific to ganglioside GD1b. Neurology 2001;56:1227-1229.

11. Kusunoki S, Chiba A, Kon K, Ando S, Arisawa K, Tate A, et al. N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barré syndrome. Ann Neurol 1994;35:570-576.

12. Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Arch Neurol 2007;64:1519-1523.

13. Koga M, Yuki N, Hirata K. Antiganglioside antibody in patients with Guillain-Barré syndrome who show bulbar palsy as an initial symptom. J Neurol Neurosurg Psychiatry 1999;66:513-516.

14. Paparounas K. Anti-GQ1b ganglioside antibody in peripheral nervous system disorders: pathophysiological role and clinical relevance. Arch Neurol 2004;61:1013-1016.

15. Odaka M, Yuki N, Hirata K. Anti-GQ1b IgG antibody syndrome: clinical and immunological range. J Neurol Neurosurg Psychiatry 2001;70:50-55.

16. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1999;35:677-679.

17. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 1999;122(Pt 12):2591-2625.

18. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978;2:750-753.

19. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barré syndrome associated with Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995;118(Pt 1):143-153.

20. Ho TW, Willison HJ, Nachamkin I, Li CY, Veitch J, Ung H, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol 1999;45:168-173.

21. Willison HJ. Gangliosides as targets for autoimmune injury to the nervous system. J Neuroimmunol 2007;193:143-149.

22. Suzuki K, Rashband MN, Tohyama K, Koibuchi K, Okamoto S, Furakoshi K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007;27:3956-3967.

23. Suzuki K, Baba H, Tohyama K, Kanai K, Kuwabara S, Hirata K, et al. Gangliosides contribute to stability of paranodal junctions and ion channel clusters in myelinated nerve fibers. Glia 2007;55:746-757.

24. Kusunoki S, Chiba A, Kon K, Ando S, Arisawa K, Tate A, et al. N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1999;66:513-516.

25. Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Arch Neurol 2007;64:1519-1523.

26. Cusumano S, Koga M, Hirata K. Antiganglioside antibody in peripheral nervous system disorders: pathophysiological role and clinical relevance. Arch Neurol 2004;61:1013-1016.

27. Paparounas K. Anti-GQ1b ganglioside antibody in peripheral neuropathies and anti-glycolipid antibodies. Brain 1999;122(Pt 12):2591-2625.

28. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978;2:750-753.

29. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/San-doglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 1998;44:780-788.

30. Ho TW, Misu B, Li CY, Gao CY, Correllah DR, Griffin JW, et al. Guillain-Barré syndrome variant with prominent facial diplegia. J Neurol Neurosurg Psychiatry 1999;66:513-516.

31. Gong Y, Tagawa Y, Lunn MP, Laroy W, Heffer-Lauc M, Li CY, et al. Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain 2002;125(Pt 11):2491-2506.

32. Galassi G, Susuki K, Quaglino D, Yuki N. Post-infectious acute ataxia and facial diplegia associated with anti-GD1a IgG antibody. Eur J Neurology 2004;11:790-791.

33. Kim SY, Kim JK, Suh CK. Polycranial neuropathy and sensory ataxia with IgG anti-GD1a antibody as a variant of Guillain-Barré syndrome. J Clin Neurol Sci 2012;114:1345-1347.

34. Hong YH, Sang JI, Oh MY, Moon HJ, Park KS, Lee KW. Axonal conduction block at intermediate nerve segments in pure motor Guillain-Barré syndrome. J Peripher Nerv Syst 2011;16:37-46.